BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Clinical trial NCT04649385 · COMPLETED

Trial details

NCT number: NCT04649385
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2021-03-04
Primary completion: 2025-10-17
Enrollment: 157

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.